124 related articles for article (PubMed ID: 31584350)
1. Thrombolysis with rhPro-UK 3 to 6 hours after embolic stroke in rat.
Hao CH; Ding WX; Sun Q; Li XX; Wang WT; Zhao ZY; Tang LD
Neurol Res; 2019 Nov; 41(11):1034-1042. PubMed ID: 31584350
[No Abstract] [Full Text] [Related]
2. Effect of human recombinant prourokinase(rhpro-UK) on thromboembolic stroke in rats.
Hao CH; Ding WX; Sun Q; Li XX; Wang WT; Zhao ZY; Tang LD
Eur J Pharmacol; 2018 Jan; 818():429-434. PubMed ID: 29154937
[TBL] [Abstract][Full Text] [Related]
3. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
Zhang L; Zhang ZG; Zhang RL; Lu M; Krams M; Chopp M
Stroke; 2003 Jul; 34(7):1790-5. PubMed ID: 12805500
[TBL] [Abstract][Full Text] [Related]
4. Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial.
Song H; Wang Y; Ma Q; Chen H; Liu B; Yang Y; Zhu J; Zhao S; Jin X; Li Y; Wang Y; Zhu R; Zhao L; Liu J; Feng W; Liu R; Ji X; Wang Y
CNS Drugs; 2024 Jan; 38(1):67-75. PubMed ID: 38030867
[TBL] [Abstract][Full Text] [Related]
5. FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model.
Okubo S; Igarashi H; Kanamatsu T; Hasegawa D; Orima H; Katayama Y
Brain Res; 2007 Apr; 1143():221-7. PubMed ID: 17316578
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant human prourokinase on thrombolysis in a rabbit model of thromboembolic stroke.
Hao C; Ding W; Xu X; Sun Q; Li X; Wang W; Zhao Z; Tang L
Biomed Rep; 2018 Jan; 8(1):77-84. PubMed ID: 29387392
[TBL] [Abstract][Full Text] [Related]
7. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
Lu HT; Zhao JG; Li MH; Li YD
Brain Res; 2012 Feb; 1438():75-84. PubMed ID: 22227456
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Phase IIa Randomized Clinical Trial.
Song H; Wang Y; Ma Q; Chen H; Liu B; Yang Y; Zhu J; Zhao S; Jin X; Li Y; Wang Y; Zhu R; Zhao L; Liu J; Ma Q; Lin Y; Tian X; Zhang Q; Zhou W; Zhang Y; Zhou J; Li Y; Song Z; Feng W; Liu R; Ji X; Wang Y
Transl Stroke Res; 2022 Dec; 13(6):995-1004. PubMed ID: 35505174
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A
J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
Ma Y; Li L; Niu Z; Song J; Lin Y; Zhang H; Du G
Pharmacol Res; 2016 May; 107():291-299. PubMed ID: 27038532
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke--an MRI study.
Kollmar R; Henninger N; Bardutzky J; Schellinger PD; Schäbitz WR; Schwab S
Exp Neurol; 2004 Nov; 190(1):204-12. PubMed ID: 15473993
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial.
Song H; Wang Y; Ma Q; Feng W; Liu R; Lv X; Huang L; Li Y; Yang Y; Geng D; Zhu J; Wei Y; Chen H; Zhu R; Zhai Q; Guo J; Liu B; Zhao S; Wang Y;
JAMA Netw Open; 2023 Jul; 6(7):e2325415. PubMed ID: 37490291
[TBL] [Abstract][Full Text] [Related]
13. Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
Wang Z; Shan W; Cao J; Wintermark M; Huang W; Zuo Z
J Neurosci Res; 2018 Mar; 96(3):449-458. PubMed ID: 28976017
[TBL] [Abstract][Full Text] [Related]
14. Monteplase reduces infarct volume and hemorrhagic transformation in rat model of embolic stroke.
Muramatsu H; Igarashi H; Okubo S; Katayama Y
Neurol Res; 2002 Apr; 24(3):311-6. PubMed ID: 11958428
[TBL] [Abstract][Full Text] [Related]
15. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
[TBL] [Abstract][Full Text] [Related]
16. Comparison of quantitative estimation of intracerebral hemorrhage and infarct volumes after thromboembolism in an embolic stroke model.
Eriksen N; Rasmussen RS; Overgaard K; Johansen FF; Pakkenberg B
Int J Stroke; 2014 Aug; 9(6):802-10. PubMed ID: 22928632
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
18. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model.
Shuaib A; Xu Wang C; Yang T; Noor R
Stroke; 2002 Dec; 33(12):3033-7. PubMed ID: 12468809
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
20. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Yang Y; Li Q; Yang T; Hussain M; Shuaib A
J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
